Barclays Raises Phibro Animal Health (NASDAQ:PAHC) Price Target to $13.00

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) had its price target lifted by research analysts at Barclays from $10.00 to $13.00 in a report issued on Friday, Benzinga reports. The firm presently has an "underweight" rating on the stock. Barclays's price objective points to a potential downside of 25.93% from the stock's previous close.

Separately, StockNews.com raised Phibro Animal Health from a "hold" rating to a "buy" rating in a research note on Tuesday, April 9th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $14.75.

Phibro Animal Health Stock Performance

NASDAQ:PAHC traded down $0.15 during midday trading on Friday, reaching $17.55. 127,605 shares of the company traded hands, compared to its average volume of 151,574. The company has a fifty day moving average price of $13.57 and a 200 day moving average price of $12.07. Phibro Animal Health has a twelve month low of $9.40 and a twelve month high of $17.89. The firm has a market capitalization of $710.83 million, a price-to-earnings ratio of 48.75, a price-to-earnings-growth ratio of 6.30 and a beta of 0.63. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.12 and a quick ratio of 1.60.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last released its earnings results on Wednesday, February 7th. The company reported $0.33 EPS for the quarter, beating the consensus estimate of $0.27 by $0.06. The business had revenue of $249.90 million during the quarter, compared to analyst estimates of $242.91 million. Phibro Animal Health had a net margin of 1.51% and a return on equity of 16.67%. On average, analysts expect that Phibro Animal Health will post 1.12 EPS for the current fiscal year.

Institutional Trading of Phibro Animal Health

A number of hedge funds have recently modified their holdings of PAHC. China Universal Asset Management Co. Ltd. lifted its stake in Phibro Animal Health by 358.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,357 shares of the company's stock worth $27,000 after acquiring an additional 1,843 shares in the last quarter. Fidelis Capital Partners LLC acquired a new stake in shares of Phibro Animal Health during the first quarter worth approximately $46,000. Quest Partners LLC acquired a new position in Phibro Animal Health in the 4th quarter worth about $56,000. Tower Research Capital LLC TRC grew its stake in shares of Phibro Animal Health by 549.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,200 shares of the company's stock valued at $95,000 after buying an additional 6,938 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in Phibro Animal Health by 19.2% in the fourth quarter. Nisa Investment Advisors LLC now owns 8,500 shares of the company's stock worth $98,000 after buying an additional 1,370 shares during the last quarter. Hedge funds and other institutional investors own 99.34% of the company's stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.